Greater First Year Effectiveness Drives Favorable Cost-Effectiveness of Brand Risedronate Versus Generic or Brand Alendronate: Modeled Canadian Analysis

Osteoporosis International - United Kingdom
doi 10.1007/s00198-007-0504-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment

PLoS ONE
Multidisciplinary
2012English

Brand-Name Versus Generic: The Authors Respond

Health Affairs
MedicineHealth Policy
2007English

Cost-Effectiveness of Teriparatide Compared With Alendronate and Risedronate for the Treatment of Postmenopausal Osteoporosis Patients in Iran

Medical Journal of the Islamic Republic of Iran
Medicine
2017English

Effectiveness of Brand Management Key Elements in Forming Consumer Loyalty

Sebelas Maret Business Review
2019English

Cost-Effectiveness Analysis

Dental Abstracts
2012English

Cost-Effectiveness Analysis.

BMJ
1993English

Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Cost-Effectiveness Analysis of Ceftriaxone Generic and Patent in Children With Typhoid

International Journal of Applied Pharmaceutics
Pharmaceutical Science
2018English

PMS71 Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy